Daniele Santini

Pubblicazioni

Titolo Pubblicato in Anno
Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria? BIOMEDICINES 2024
Sarcopenia in Breast Cancer Patients: A Systematic Review and Meta-Analysis CANCERS 2024
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care PROSTATE CANCER AND PROSTATIC DISEASES 2024
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? EUROPEAN UROLOGY ONCOLOGY 2024
Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2024
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line JOURNAL OF TRANSLATIONAL MEDICINE 2024
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study THE ONCOLOGIST 2024
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis BMC CANCER 2024
Co-Occurrence of ALK rearrangement and KRAS G12C mutation in NSCLC: Report of two cases CURRENT PROBLEMS IN CANCER. CASE REPORTS 2024
Systemic treatment of mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer-single versus double checkpoint inhibition ESMO OPEN 2024
Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 2024
The role of CD73 in predicting the response to immunotherapy in head and neck cancer patients PATHOLOGY RESEARCH AND PRACTICE 2024
Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis BMC CANCER 2024
Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A Systematic Review and Individual Patient Data (IPD) Meta-Analysis CURRENT ONCOLOGY 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1) TARGETED ONCOLOGY 2024
Testicular ultrasonographic features predict future risk for bilateral testicular germ cell tumour: A long-term single centre follow-up study ANDROLOGY 2024
Correction to: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (npj Breast Cancer, (2024), 10, 1, (58), 10.1038/s41523-024-00657-z) NPJ BREAST CANCER 2024
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy CLINICAL CANCER RESEARCH 2024
Assessing risks and knowledge gaps on the impact of systemic therapies in early breast cancer on female fertility: A systematic review of the literature CANCER TREATMENT REVIEWS 2024
Blood Extracellular Vesicles beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk Non-Muscle-Invasive Bladder Cancer Patients BIOMEDICINES 2024

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma